Sicare Bio
SiCare Bio is a pharmaceutical technology company developing nanoporous silicon dioxide (nPSi) particle platforms for targeted and extended-release drug delivery. It serves pharmaceutical partners through custom co-development agreements across multiple therapeutic areas including ARMD, mRNA, oncology, and neurology.
- Company typePrivate
- Founded2024
- HeadquartersKapolei, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sicare Bio does
SiCare Bio is a pharmaceutical technology company operating as a business division of TruTag Technologies, Inc., headquartered in Kapolei, Hawaii, and launched in late 2024. The company commercializes the SiRx platform, a programmable drug delivery system built on high-precision nanoporous silicon dioxide (nPSi) particles engineered for the loading and sustained release of therapeutic payloads. Two product formats are offered: nPSi nanoparticles for targeted delivery of biologics and small molecules (including siRNA, mRNA, antibodies, and chemotherapeutics), and nPSi microparticles (pSiMPs) for extended-release applications. The platform is positioned to address specific shortcomings of existing drug delivery systems, notably lipid nanoparticle (LNP) limitations such as endosomal entrapment, and polymer-based systems' incompatibility with proteins and burst-release profiles.
The company operates as a B2B pharmaceutical partner, generating revenue through direct strategic co-development agreements with pharmaceutical companies. SiCare Bio engineers custom particles for each partner's unique therapeutic load and release profile, with revenue derived from development agreements and potential licensing of the SiRx platform. The disclosed pipeline spans six therapeutic areas: Age-Related Macular Degeneration (partnered with Spinnaker BioSciences, preclinical stage), mRNA Delivery, Oncology, Immunology, Contraception, and Neurology (all currently in discovery with undisclosed pharmaceutical partners).
Leadership comprises a six-person executive team with credentials spanning pharmaceutical quality (ex-Abbott, Kos Pharmaceuticals), porous silicon research (Michael Sailor with over 200 publications and 25+ patents), biotech commercialization, and law. The underlying nPSi manufacturing capability is built on more than a decade of R&D and scaled production by parent TruTag Technologies, which supplies kilograms-per-annum capacity. No external funding rounds or revenue figures are publicly disclosed.
Sicare Bio firmographics
Firmographics- Name
- Sicare Bio
- Legal name
- TruTag Technologies, Inc.
- Website
- https://sicarebio.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SiCare Bio is a pharmaceutical technology company developing nanoporous silicon dioxide (nPSi) particle platforms for targeted and extended-release drug delivery. It serves pharmaceutical partners through custom co-development agreements across multiple therapeutic areas including ARMD, mRNA, oncology, and neurology.
- Ownership category
- akta.pro rank
Sicare Bio industry classification
Industry- Product category
- Pharmaceutical Drug Delivery Technology
- NAICS
- Research and Development in Nanotechnology (541713)
- SIC
- Miscellaneous Chemical Products (2890)
- akta.pro primary industry
- RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)
- akta.pro secondary industry
- Silica (Quartz, Fumed, Precipitated) (IMAEAFAD)
Keywords
Where Sicare Bio is headquartered
LocationHeadquarters
- HQ city
- Kapolei
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Sicare Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development Partnerships: SiCare Bio generates revenue through strategic partnerships with pharmaceutical companies, engineering custom nPSi particles for each partner's unique therapeutic load and release profile. Revenue is derived from development agreements and potentially licensing of the SiRx platform technology.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Sicare Bio product offering
Product offeringCore offering
SiCare Bio engineers custom nanoporous silicon (nPSi) particles through its SiRx platform, a programmable drug delivery system that loads and sustains the release of therapeutic payloads for pharmaceutical development partners. The company offers two delivery modalities: nPSi nanoparticles for targeted delivery of biologics and small molecules (siRNA, mRNA, antibodies, chemotherapeutics), and nPSi microparticles (pSiMPs) for extended-release applications.
Product overview
SiCare Bio offers the SiRx platform, a core technology comprising high-precision, nanoporous silicon dioxide (nPSi) particles that serve as a programmable drug delivery system for pharmaceutical applications. The platform encompasses two primary product offerings: nPSi nanoparticles for targeted delivery of biologics and small molecules (including siRNA, mRNA, antibodies, and chemotherapeutics), and nPSi microparticles (pSiMPs) for extended-release drug delivery. The company operates pipeline programs across multiple therapeutic areas including ARMD (partnered with Spinnaker BioSciences), mRNA delivery, oncology, immunology, contraception, and neurology, all leveraging the core SiRx platform technology.
Differentiator
Problem solved
Functional benefit
Brands
- SiRx Platform: SiRx is the company's precision nanoporous silicon dioxide particle platform for delivering and sustaining release of therapeutic payloads, used as an innovative drug delivery system for development partners.
Products and services
- SiRx Platform Programmable drug delivery platform using high-precision nanoporous silicon (nPSi) particles for the loading and sustained release of therapeutic payloads, offered to pharmaceutical development partners as an innovative drug delivery system for extended-release and targeted delivery applications.
- nPSi Nanoparticles (Targeted Delivery) Engineered nanoporous silicon dioxide nanoparticles for targeted redosable delivery of biologic and small molecule payloads including siRNA, mRNA, antibodies, and chemotherapeutics, addressing shortcomings of lipid nanoparticle (LNP) drug delivery systems.
- nPSi Microparticles (pSiMPs - Extended-Release Delivery) Nanoporous silicon dioxide microparticles (pSiMPs) for extended-release drug delivery in which nanopores are filled with active pharmaceutical ingredient and released as particles break down in the body, offering advantages over traditional polymer-based systems including improved tolerability, custom release profiles, and aqueous-based loading compatible with proteins.
Companies that use Sicare Bio
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Sicare Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Sicare Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Spinnaker BioSciencescoreSpinnaker BioSciences is partnered with SiCare Bio for ARMD (Age-Related Macular Degeneration) drug delivery application. The partnership is currently in preclinical stage, utilizing the SiRx platform for therapeutic delivery.
- TruTag TechnologiescoreTruTag Technologies is the parent company of SiCare Bio. SiCare Bio was launched in late 2024 as a business division of TruTag Technologies, which is the global leader in manufacturing of high-precision, bio-compatible nanoporous silica. TruTag has dedicated over a decade of R&D to scalable manufacturing of these materials.
- Undisclosed Pharmaceutical PartnerscoreMultiple undisclosed pharmaceutical partners are working with SiCare Bio on various therapeutic applications including mRNA Delivery, Oncology, Immunology, Contraception, and Neurology - all currently in Discovery stage.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Sicare Bio competitors and assessment
Company assessmentBroad incumbents
- Precision NanoSystems (Cytiva / Danaher): Precision Nanosystems (now part of Cytiva/Danaher) provides lipid nanoparticle development equipment and services for RNA and gene therapy developers — comparable as an incumbent RNA delivery tooling/services player operating in the same pharma partnership funnel.
- BioNTech: BioNTech is a leading mRNA therapeutics company with its own LNP formulation capabilities and multiple partnered programs — comparable as a broad incumbent shaping industry adoption of mRNA delivery technology.
- Alnylam Pharmaceuticals: Alnylam pioneered the GalNAc-conjugate siRNA delivery platform and remains the incumbent in hepatocyte-targeted RNA delivery — comparable as a dominant RNA delivery paradigm against which any new delivery platform (like SiRx) competes for therapeutic partnership demand.
- Catalent: Catalent provides drug delivery and formulation development services (including advanced biologics delivery) to pharma partners — comparable as a broad incumbent in development-stage delivery services with a partnership-driven GTM motion.
- Becton Dickinson (BD): BD's Pharmaceutical Systems segment supplies drug delivery devices (prefilled syringes, auto-injectors, needle-free systems) — comparable as an established pharma delivery incumbent whose customers overlap with SiCare Bio's target buyer base.
- West Pharmaceutical Services: West is a leading provider of drug delivery systems and containment for injectable therapeutics — comparable as a broader incumbent in pharmaceutical delivery and primary-packaging systems serving large pharma partners.
Direct peers
- Acuitas Therapeutics: Acuitas is the leading LNP delivery platform provider for nucleic acid therapeutics, partnering with multiple mRNA and gene-editing developers — the most direct comparable to SiCare Bio's SiRx delivery platform, which is positioned as an LNP alternative.
- Arcturus Therapeutics: Arcturus develops its own LNP delivery platform (LUNAR) for mRNA and siRNA therapeutics and licenses delivery to partners — a directly comparable integrated delivery platform + pipeline model with strong RNA delivery focus.
- Genevant Sciences: Genevant commercializes LNP and ligand-based nucleic acid delivery technology through partnerships with RNA therapeutic developers — directly comparable to SiCare Bio as an LNP-alternative delivery platform targeting siRNA/mRNA partners.
Emerging players
- Codiak BioSciences: Codiak developed engineered exosome-based delivery for RNA and protein therapeutics — comparable as an early-stage non-LNP, non-viral delivery platform seeking pharma partners for pipeline assets in oncology and immunology.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Sicare Bio social profiles
Digital presenceSicare Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sicare Bio leadership team
Management profileNumber of profiles
Profiles6 records
Sicare Bio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sicare Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sicare Bio
What does Sicare Bio do?
SiCare Bio engineers custom nanoporous silicon (nPSi) particles through its SiRx platform, a programmable drug delivery system that loads and sustains the release of therapeutic payloads for pharmaceutical development partners. The company offers two delivery modalities: nPSi nanoparticles for targeted delivery of biologics and small molecules (siRNA, mRNA, antibodies, chemotherapeutics), and nPSi microparticles (pSiMPs) for extended-release applications.
Is Sicare Bio a public or private company?
Sicare Bio is a private company. It is classified as corporate owned and is currently operating.
When was Sicare Bio founded?
Sicare Bio was founded in 2024. It employs 1 to 10 people.
Where is Sicare Bio based?
Sicare Bio is headquartered in Kapolei, United States, in the North America region.
How does Sicare Bio make money?
One revenue line is on record: pharmaceutical Development Partnerships.
Who are Sicare Bio's main competitors?
Broad incumbents on record are Precision NanoSystems (Cytiva / Danaher), BioNTech, Alnylam Pharmaceuticals, Catalent, Becton Dickinson (BD) and West Pharmaceutical Services. Direct peers are Acuitas Therapeutics, Arcturus Therapeutics and Genevant Sciences. Codiak BioSciences is listed as an emerging player.
Does Sicare Bio have an API?
No public API is recorded for Sicare Bio.
What industry is Sicare Bio in?
Sicare Bio's product category is Pharmaceutical Drug Delivery Technology. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of IMAEAFAD, Silica (Quartz, Fumed, Precipitated). Its NAICS code is 541713 and its SIC code is 2890.